5:58 PM
 | 
Mar 03, 2014
 |  BC Extra  |  Company News

RedHill resubmits RHB-103 for migraines

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) and partner IntelGenx Corp. (TSX-V:IGX; OTCQX:IGXT) resubmitted an NDA to FDA for RHB-103 to treat acute migraines. The partners...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >